Nektar Therapeutics (NASDAQ: NKTR) NKTR-181 is a new opioid pain killer that passes through the blood brain barrier more slowly than existing opiates, and that means it produces less of the euphoria that causes opioid dependency. With phase 3 data on hand and the hunt for a collaboration partner ongoing, NKTR-181 might become a viable alternative to traditional opioids in treating conditions like chronic back pain.
In this clip from The Motley Fool's Industry Focus: Healthcare podcast, Todd Campbell joins analyst Kristine Harjes to discuss NKTR-181's future.
Continue Reading Below
A full transcript follows the video.
10 stocks we like better than Nektar TherapeuticsWhen investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.*
David and Tom just revealed what they believe are the 10 best stocks for investors to buy right now... and Nektar Therapeutics wasn't one of them! That's right -- they think these 10 stocks are even better buys.
Click here to learn about these picks!
*Stock Advisor returns as of April 3, 2017
This video was recorded on April 12, 2017.
Kristine Harjes:We talk about the mu-opioid receptors as compared to the kappa-antagonists. The mu ones arepretty much going to be more effective than targeting kappa every time; it's just the nature of the biology there. So CR845 probably won't ever completely replace mu receptors, butthere is a company out there calledNektar Therapeuticsthat is trying to develop a mu-opioid receptor-targeting drug thatcrosses the blood-brain barrier, but it does so slowly. The point there is to reduce the euphoria and also lessen the risk of abuse.
Todd Campbell:Right. It's also more selective in how it's targeting those mu receptors. It'stargeting more selectively; it'spassing more slowly through the blood-brain barrier. Andas a result, you're getting a similarefficacy of pain relief, but you're also gettingless of the likelihood of the euphoria. Intough-to-treat pain cases,chronic pain cases,that could be a major advantage for this company. Now, we'vealready seen a positive read-out in late-stage studies for this drug. The company itself has a history, a strategy, where it likes tolicense these drugs out to other larger players, and ithas said that it's going to beevaluating its options with this drug now. So perhaps they announce alicensing deal over the course of the coming months. Then, once that's done, maybe this drug gets filed for FDA approvalrelatively shortly thereafter.
Harjes:Right. It seems like they'reall done testing it. They have proven it's very effective,and at this point, they'rejust looking for a partner. And at that point, it will file with the FDA. When and if it gets there, we canprobably expect around a mid-teens royalty. That seems to be fairlytypical for this company. It'skind of an interesting strategy in general.I would say it probably makes the upside a little bit more contained,but it's also less risky.
Campbell:It's less risky,and it keeps the dollars flowing in for them to work on other projects they have going on.I think it's an interesting company. The stock has moved a lot since itannounced the results from itschronic-back-pain study last month.Investors have to recognize that it'smaybe not as cheap as it was four or six weeks ago. But certainly something to keep an eye on,especially given the fact that you could get some news in a not very long period of time of somebody is signing on to commercialize it.
Kristine Harjes has no position in any stocks mentioned. Todd Campbell has no position in any stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.